The Indian Pharmacopoeia Commission (IPC) has added 23 new impurities standards and 7 new Indian Pharmacopoeial Reference standards
Acute therapies continue to report strong growth compared to chronic ones.
Post normalisation of high growth months of April and May this year the average IPM growth from June to August this year stood at 15.2 % YoY : Ind-Ra reports
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Domestic business was up 41.9% YoY and 27.7% QoQ
Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
Domestic market and developing countries will need doses of Indian vaccines
Demand normalisation post the second wave contributed to the steady growth
Subscribe To Our Newsletter & Stay Updated
